Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 11/20 | 0.46 |
| ▸ | LIPG | Q9Y5X9 | 11/20 | 0.46 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA3 | P07451 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.42 |
| ▸ | F11 | P03951 | 1/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29730121 | 1.00 | LPL (0.46) | LPLLIPGDGAT1CA1CA2 | |
| SCHEMBL16278109 | 1.00 | LPL (0.46) | LPLLIPGDGAT1CA1CA2 | |
| SCHEMBL15661734 | 0.86 | LIPG (0.57) | LPLLIPGDGAT1CA1CA2 | |
| SCHEMBL4331624 | 0.82 | NOS3 (0.38) | LPLLIPGDGAT1F11NOS3 | |
| SCHEMBL19472 | 0.82 | KDM4E (0.43) | DGAT1CA1CA2CA9CA12 | |
| SCHEMBL20068614 | 0.81 | DGAT1 (0.56) | LPLLIPGDGAT1CA1CA2 | |
| SCHEMBL18071 | 0.80 | CA1 (0.47) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL31219310 | 0.79 | LPL (0.47) | LPLLIPGDGAT1CA1CA2 | |
| SCHEMBL42112 | 0.79 | LPL (0.47) | LPLLIPGDGAT1CA1CA2 | |
| SCHEMBL16006727 | 0.79 | DGAT1 (0.48) | LPLLIPGDGAT1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1676 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12172991-B2 | Bicycle topoisomerase i inhibiting compounds, process for preparation and use thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2024-12-24 | — | — | US | claimed |
| US-20210246128-A1 | BICYCLE TOPOISOMERASE I INHIBITING COMPOUNDS, PROCESS FOR PREPARATION AND USE THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2021-08-12 | — | — | US | claimed |
| EP-3807248-A1 | BICYCLE TOPOISOMERASE I INHIBITING COMPOUNDS, PROCESS FOR PREPARATION AND USE THEREOF | Council of Scientific and Industrial Research (IN) | 2021-04-21 | — | — | EP | claimed |
| EP-4747241-A1 | BENZIMIDAZOLE DERIVATIVES | Syngenta Crop Protection AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| US-20260137706-A1 | METHODS OF TREATING INFLAMMATORY DISEASES | INTERLINE THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| WO-2026102082-A1 | ALKYLPHENYL SUBSTITUTED COMPOUNDS, COMPOSITIONS AND METHODS OF USE | DEEP APPLE THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260132119-A1 | Alkylphenyl Substituted Compounds, Compositions and Methods of Use | DEEP APPLE THERAPEUTICS, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| EP-3911640-B1 | PCSK9 INHIBITORS FOR USE IN THERAPY, ESPECIALLY THE TREATMENT OF CARDIOVASCULAR DISEASE | ASTRAZENECA AB (SE) | 2026-05-13 | — | — | EP | disclosed |
| US-12606556-B2 | TYK-2 inhibitor | BEONE MEDICINES I GMBH (CH) | 2026-04-21 | — | — | US | disclosed |
| EP-4724440-A1 | METHODS OF TREATING INFLAMMATORY DISEASES | Interline Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12600728-B2 | Interleukin-17 inhibitors | NOVARTIS AG (CH) | 2026-04-14 | — | — | US | disclosed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
| EP-1737459-A1 | IMIDAZOPYRIDINE AND IMIDAZOPYRIMIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | Warner-Lambert Company LLC (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2006099231-A1 | PYRIMIDINE DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006076575-A2 | SUBSTITUTED BIARYL COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-07-20 | — | — | WO | disclosed |
| US-20060154915-A1 | Substituted biaryl compounds as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-07-13 | — | — | US | disclosed |
| US-20050277640-A1 | Pyrimidine derivatives for treatment of hyperproliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-12-15 | — | — | US | disclosed |
| WO-2005089763-A1 | IMIDAZOPYRIDINE AND IMIDAZOPYRIMIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12606556-B2 | TYK-2 inhibitor | TYK2, TXK, JAK1 | LPL 4528/4885LIPG 4402/4885DGAT1 2688/4885 |
| US-20260137706-A1 | METHODS OF TREATING INFLAMMATORY DISEASES | NR3C1, CCR1, CXCR2 | LPL 701/4885LIPG 511/4885DGAT1 1191/4885 |
| US-20060154915-A1 | Substituted biaryl compounds as factor XIa inhibitors | TFPI, F3, F12 | LPL 1371/4885LIPG 266/4885DGAT1 4293/4885 |
| US-12172991-B2 | Bicycle topoisomerase i inhibiting compounds, process for preparation and use thereof | TOP1, TOP2A, TOP2B | LPL 3186/4885LIPG 2436/4885DGAT1 4292/4885 |
| US-20260132119-A1 | Alkylphenyl Substituted Compounds, Compositions and Methods of Use | GIPR, MC2R, GRPR | LPL 635/4885LIPG 1013/4885DGAT1 2075/4885 |
| US-20050277640-A1 | Pyrimidine derivatives for treatment of hyperproliferative disorders | TYMP, DPYD, CCNA2 | LPL 4366/4885LIPG 3441/4885DGAT1 3309/4885 |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | MAP3K1, MAP3K5, MAP3K2 | LPL 3851/4885LIPG 2157/4885DGAT1 4239/4885 |
| US-20210246128-A1 | BICYCLE TOPOISOMERASE I INHIBITING COMPOUNDS, PROCESS FOR PREPARATION AND USE THEREOF | TOP1, TOP2A, TOP2B | LPL 3186/4885LIPG 2436/4885DGAT1 4292/4885 |
| US-12600728-B2 | Interleukin-17 inhibitors | IL17A, IL2, IL1B | LPL 4001/4885LIPG 4589/4885DGAT1 2928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.